QN-030a

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Zhejiang University

Conditions

AML, AdultMinimal Residual Disease

Phase 1

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

TerminatedNCT05601830

Institute of Hematology & Blood Diseases Hospital, ChinaMinimal Residual Disease

Start: 2022-10-09End: 2023-06-30Updated: 2024-11-06

Natural Killer(NK) Cell Therapy in r/r AML

Zhejiang UniversityAML, Adult

Start: 2022-12-24End: 2025-12-24Target: 18Updated: 2023-01-03